Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
Go back to Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection| Empire Insurance Co (NASDAQ: EIGR) | Delayed: 1.73 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.73 | 52 Week High | $23.10 | |||
| Open | $63.25 | 52 Week Low | $10.71 | |||
| Day High | $1.73 | P/E | N/A | |||
| Day Low | $1.73 | EPS | $0.00 | |||
| Volume | 457,358 | |||||
